Investors Target Grail, Inc. Following 50% Share Price Collapse

The legal action, led by the firm Levi & Korsinsky, focuses on the window between May 13, 2025, and February 19, 2026. During this period, management repeatedly characterized the 140,000-participant trial as a robust success, citing positive predictive values and promising real-world performance. Investors allege these optimistic updates concealed internal data showing the study was not sufficiently powered to detect a reduction in late-stage cancers.

Despite repeated inquiries from analysts regarding statistical specifics, company leadership consistently withheld granular data, citing the need to protect the trial's integrity. This strategy of selective disclosure kept market expectations high until the February 19 revelation that the expected reduction in Stage III and IV cancers was not observed. The company’s subsequent suggestion that the trial required a longer follow-up period contradicted earlier assurances that the three-year study design was adequate for its stated goals.

Investors who purchased shares during the class period and suffered losses have until August 4, 2026, to apply for lead plaintiff status. The litigation seeks to address the gap between the company's public confidence and the underlying trial results that ultimately shattered shareholder value.